OP 5558
Alternative Names: OP-5558Latest Information Update: 04 Feb 2022
At a glance
- Originator ORIC Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action 5-nucleotidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma